Brokerages Expect Kiniksa Pharmaceuticals Ltd (KNSA) to Post -$0.50 Earnings Per Share
Brokerages predict that Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) will post earnings of ($0.50) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Kiniksa Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.55) and the highest is ($0.45). The business is expected to issue its next quarterly earnings report on Monday, November 5th.
According to Zacks, analysts expect that Kiniksa Pharmaceuticals will report full-year earnings of ($2.64) per share for the current year, with EPS estimates ranging from ($2.71) to ($2.56). For the next fiscal year, analysts anticipate that the company will post earnings of ($3.04) per share, with EPS estimates ranging from ($3.08) to ($2.99). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for Kiniksa Pharmaceuticals.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings data on Monday, August 6th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.53).
In other news, major shareholder Cormorant Asset Management, Lp bought 69,444 shares of the stock in a transaction dated Tuesday, May 29th. The shares were acquired at an average price of $18.00 per share, with a total value of $1,249,992.00. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Bros. Advisors Lp Baker bought 3,000,000 shares of the stock in a transaction dated Tuesday, May 29th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $54,000,000.00. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 3,912,796 shares of company stock worth $71,248,379.
Large investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC bought a new stake in Kiniksa Pharmaceuticals during the 2nd quarter worth about $115,000. BlackRock Inc. bought a new stake in Kiniksa Pharmaceuticals during the 2nd quarter worth about $173,000. Quantitative Systematic Strategies LLC bought a new stake in Kiniksa Pharmaceuticals during the 2nd quarter worth about $348,000. Alps Advisors Inc. bought a new stake in Kiniksa Pharmaceuticals during the 2nd quarter worth about $371,000. Finally, Dean Capital Investments Management LLC bought a new stake in Kiniksa Pharmaceuticals during the 2nd quarter worth about $535,000. 0.42% of the stock is currently owned by hedge funds and other institutional investors.
Shares of KNSA stock traded down $0.42 during mid-day trading on Friday, reaching $15.94. The company’s stock had a trading volume of 226,700 shares, compared to its average volume of 90,161. Kiniksa Pharmaceuticals has a 1-year low of $13.04 and a 1-year high of $24.64.
Kiniksa Pharmaceuticals Company Profile
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.